This inventor holds 1 USPTO granted patent and 1 published patent application. Top assignees: The Rockefeller University, The State University of New York. Active years: 2014.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile
Company Filing History:


Years Active: 2014
Title: Ruchi Gupta: Innovator in Protein Variant Research
Introduction
Ruchi Gupta is a prominent inventor based in New York, NY (US). She has made significant contributions to the field of protein research, particularly in the development of Nucleobindin-1 (NUCB1) protein variants. Her innovative work focuses on addressing amyloid fibril formation, which is crucial in various medical conditions.
Latest Patents
Ruchi Gupta holds a patent for "Nucleobindin I variant protein compositions and methods of use." This invention relates to NUCB1 protein variants that can disaggregate amyloid fibrils and inhibit their formation in the presence of physiological concentrations of calcium. The patent encompasses isolated NUCB1 protein variants, nucleic acids encoding these variants, cells containing the isolated nucleic acids, pharmaceutical compositions, and kits that include the variants. Additionally, it outlines methods for creating these variants and their therapeutic applications. She has 1 patent to her name.
Career Highlights
Throughout her career, Ruchi Gupta has worked with esteemed institutions such as The Rockefeller University and The State University of New York. Her research has garnered attention for its potential impact on therapeutic strategies for diseases associated with amyloid fibrils.
Collaborations
Ruchi Gupta has collaborated with notable professionals in her field, including Neeraj Kapoor and Santosh T Menon. These collaborations have contributed to her innovative research and development efforts.
Conclusion
Ruchi Gupta's work in protein variant research exemplifies the importance of innovation in addressing complex medical challenges. Her contributions continue to pave the way for advancements in therapeutic applications.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile